Brian Christopher Krause

US Patent:

8492108, Jul 23, 2013

Filed:

Jun 14, 2010

Appl. No.:

13/377586

Inventors:

Bruce J. Auerbach - Ann Arbor MI, US
Reynold Homan - Ann Arbor MI, US
Brian Krause - Ann Arbor MI, US

International Classification:

C12Q 1/48

US Classification:

435 15

Abstract:

Disclosed are methods for treating conditions characterized by anemia or red blood cells dysfunction by administering an agent that increases the level of endogenous LCAT or LCAT activity. Additionally disclosed are methods of treating conditions wherein red blood cells have reduced function in relation to deformability, oxygenation, increased adhesion and aggregability, reduced nitric oxide function, or decreased life-span, increased free cholesterol, or abnormal phospholipid content. Also disclosed are methods for treating conditions characterized by an abnormal concentration of free cholesterol in red blood cells and methods of normalizing the free cholesterol content of red blood cells.

US Patent:

20130045194, Feb 21, 2013

Filed:

May 6, 2011

Appl. No.:

13/695919

Inventors:

Bruce J. Auerbach - Ann Arbor MI, US
Reynold Homan - Ann Arbor MI, US
Brian R. Krause - Ann Arbor MI, US

Assignee:

ALPHACORE PHARMA, LLC - Ann Arbor MI

International Classification:

A61K 38/45
A61K 38/17
A61P 5/00
A61P 15/00
A61P 17/02
A61P 1/16
A61P 13/12
A61P 19/02
A61K 31/421
A61P 31/00

US Classification:

424 945, 514376, 514 74, 514 14

Abstract:

Disclosed are compositions and methods for treating conditions characterized by low HDL-CE which can lead to decreased delivery of cholesteryl ester to steroidogenic tissues, reducing the organ's ability to produce steroids especially during periods of demand, stress and or systemic inflammatory response syndrome.

US Patent:

20140023631, Jan 23, 2014

Filed:

Jul 19, 2013

Appl. No.:

13/946236

Inventors:

Brian KRAUSE - Ann Arbor MI, US
Reynold HOMAN - Ann Arbor MI, US

Assignee:

AlphaCore Pharma, LLC - Gaithersburg MD

International Classification:

A61K 38/45

US Classification:

424 945

Abstract:

Disclosed are methods for treating conditions characterized by anemia or red blood cells dysfunction by administering an agent that increases the level of endogenous LCAT or LCAT activity. Additionally disclosed are methods of treating conditions wherein red blood cells have reduced function in relation to deformability, oxygenation, increased adhesion and aggregability, reduced nitric oxide function, or decreased life-span, increased free cholesterol, or abnormal concentration of free cholesterol in red blood cells and methods of normalizing the free cholesterol content of red blood cells.

US Patent:

20140024061, Jan 23, 2014

Filed:

Dec 28, 2011

Appl. No.:

13/977161

Inventors:

Bruce J. Auerbach - Ann Arbor MI, US
Reynold Homan - Ann Arbor MI, US
Brian Krause - Ann Arbor MI, US

International Classification:

C12Q 1/48

US Classification:

435 15

Abstract:

The present disclosure relates to methods for detecting and measuring the activity of lecithin:cholesterol acyltransferase (LCAT) in solution (e.g. serum, plasma, cell culture media, aqueous solution) with fluorescent sterol substrates. The present disclosure also relates to a method for evaluating efficacy of a therapeutic agent for stimulating LCAT and for determining endogenous LCAT activity in a patient. Also disclosed are kits that are used to carry out the aforementioned methods and methods.

US Patent:

61179094, Sep 12, 2000

Filed:

Jan 26, 1998

Appl. No.:

9/000296

Inventors:

Brian Robert Krause - Ann Arbor MI

Assignee:

Warner-Lambert Company - Morris Plains NJ

International Classification:

A61K 3118

US Classification:

514602

Abstract:

The present invention is directed to new therapeutic uses of compounds of formula: ##STR1## wherein X and Y are oxygen, sulfur, or (CR'R"). sub. n wherein n is 1 to 4; R is hydrogen, alkyl, or benzyl; R. sub. 1 and R. sub. 2 are phenyl, substituted phenyl, naphthyl, substituted naphthyl, an aralkyl group, an alkyl chain, adamantyl, or a cycloalkyl group. The uses are cerebrovascular disease such as stroke, peripheral vascular diseases, and restenosis.

US Patent:

48597031, Aug 22, 1989

Filed:

Jun 15, 1987

Appl. No.:

7/061641

Inventors:

Brian R. Krause - Ann Arbor MI

Assignee:

Warner-Lambert Company - Morris Plains NJ

International Classification:

A61K 31235
A61K 3124
A61K 31195
A61K 3116

US Classification:

514543

Abstract:

Single dose formulations containing a combination of a lipid regulating agent selected from gemfibrozil, clofibrate, bezafibrate, or fenofibrate and an ACAT inhibiting agent are effective pharmacological formulations for regulating blood serum lipid and cholesterol levels.

US Patent:

20150190479, Jul 9, 2015

Filed:

Sep 5, 2014

Appl. No.:

14/478456

Inventors:

- Gaithersburg MD, US
Reynold Homan - Ann Arbor, MI
Brian R. Krause - Ann Arbor MI, US

International Classification:

A61K 38/45
A61K 45/06
A61K 31/685
A61K 31/575
A61K 38/17

Abstract:

Disclosed are compositions and methods for treating conditions characterized by low HDL-CE which can lead to decreased delivery of cholesteryl ester to steroidogenic tissues, reducing the organ's ability to produce steroids especially during periods of demand, stress and or systemic inflammatory response syndrome.

US Patent:

20150182600, Jul 2, 2015

Filed:

Mar 12, 2015

Appl. No.:

14/656083

Inventors:

- Ann Arbor MI, US
Brian KRAUSE - Ann Arbor MI, US
Reynold HOMAN - Ann Arbor MI, US

International Classification:

A61K 38/45

Abstract:

Disclosed are methods for treating conditions characterized by anemia or red blood cells dysfunction by administering an agent that increases the level of endogenous LCAT or LCAT activity. Additionally disclosed are methods of treating conditions wherein red blood cells have reduced function in relation to deformability, oxygenation, increased adhesion and aggregability, reduced nitric oxide function, or decreased life-span, increased free cholesterol, or abnormal phospholipid content. Also disclosed are methods for treating conditions characterized by an abnormal concentration of free cholesterol in red blood cells and methods of normalizing the free cholesterol content of red blood cells.